



Achillion Pharmaceuticals  
Investor Relations Department  
300 George St.  
New Haven, CT 06511  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: ACHN**

Last Trade: 4.09

Trade Time: 4:00 PM ET  
Sep 20, 2017

Change: 0.23 ↑ (+5.959%)

Day Range: 3.82 - 4.14

52-Week Range: 3.15 - 9.19

Volume: 1,935,136

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

### Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Sep 20, 2017*  
[Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series](#)

*Sep 11, 2017*  
[Achillion Announces Strengthening of Management Team](#)

*Sep 11, 2017*  
[Achillion Announces Termination of Worldwide Collaboration for Hepatitis C With Janssen](#)

*Aug 8, 2017*  
[Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor](#)

*Aug 1, 2017*  
[Achillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017](#)

## Financial Disclosures [\[ View all \]](#)

### [Second Quarter Financial Results](#)

*Feb 23, 2017*  
[Annual Report \(10-K\)](#)

*Apr 17, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)

*May 4, 2017*  
[Quarterly Report \(10-Q\)](#)

*Nov 3, 2016*  
[Quarterly Report \(10-Q\)](#)